Focused On-demand Library for Sodium channel protein type 8 subunit alpha

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for ion channels.


 

Fig. 1. The screening workflow of Receptor.AI

This includes extensive molecular simulations of the ion channel in its native membrane environment, in open, closed, and inactivated forms, paired with ensemble virtual screening that factors in conformational mobility in each state. Tentative binding pockets are considered in the pore, the gating region, and allosteric areas to capture the full range of mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q9UQD0

UPID:
SCN8A_HUMAN

ALTERNATIVE NAMES:
Sodium channel protein type VIII subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.6

ALTERNATIVE UPACC:
Q9UQD0; B9VWG8; O95788; Q9NYX2; Q9UPB2

BACKGROUND:
Sodium channel protein type 8 subunit alpha, or Voltage-gated sodium channel subunit alpha Nav1.6, is essential for the voltage-dependent sodium ion permeability in excitable membranes, enabling Na(+) ions to move according to their electrochemical gradient. It assumes opened or closed conformations based on the membrane's voltage difference. In specific cell types, such as macrophages and melanoma cells, it contributes to podosome and invadopodia formation.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Sodium channel protein type 8 subunit alpha could open doors to potential therapeutic strategies. Its involvement in diseases like Cognitive impairment with or without cerebellar ataxia, Developmental and epileptic encephalopathy 13, Benign familial infantile seizures, and Familial myoclonus 2 underscores its significance in neurology and drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8144 of 8789